Ozempic, Wegovy, Mounjaro, and Zepbound are no longer on FDA's drug shortage list. FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Even so, a pharmacy can be out of your specific strength on a given day. The best way to find it is to call pharmacies with the exact brand, strength, and form on your prescription.

Key takeaways

  • FDA declared the tirzepatide (Mounjaro, Zepbound) shortage resolved on December 19, 2024, after an earlier October 2, 2024 decision. It declared the semaglutide (Ozempic, Wegovy) shortage resolved on February 21, 2025.
  • "Resolved" does not mean every pharmacy has every strength. Strength-by-strength gaps are the common real-world problem.
  • FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness, or quality before they are marketed.
  • Oral options now exist. FDA-approved weight-management pills include the Wegovy pill (approved December 2025) and Foundayo (approved April 2026).
  • Coverage changes often. Medicare has a temporary GLP-1 Bridge program through December 31, 2027 with a $50 monthly copay for covered drugs.

Are Ozempic, Wegovy, Mounjaro and Zepbound still in shortage?

No, not according to FDA. As of October 14, 2026, FDA's drug shortage list has no current entry for semaglutide or tirzepatide injections. Here is how the rulings went:

  • Tirzepatide (Mounjaro, Zepbound). FDA first determined the shortage resolved on October 2, 2024. On October 22, 2024, that decision was sent back for reevaluation. FDA issued a new decision on December 19, 2024, again finding the shortage resolved.
  • Semaglutide (Ozempic, Wegovy). FDA determined the shortage resolved on February 21, 2025.

FDA generally considers a drug commercially available once its shortage is resolved. That matters for compounding, which is covered below.

Why can't I find my dose?

Because these medicines come in step-up strengths, a pharmacy might carry one strength and be out of the next. A pharmacy also has to order the exact product, such as a specific pen or tablet strength, from its wholesaler. A gap in one strength can leave you with a prescription nobody can fill that week.

FDA says that when a drug is out of stock at a pharmacy, it is often a local and temporary problem. Still, if you need your next strength on a schedule, a gap is stressful. Please do not try to split a dose, combine strengths, or stretch a pen. Call your prescriber's office and ask what they recommend. Only your prescriber can change your dose or your medicine.

What about compounded semaglutide and tirzepatide?

During the shortages, FDA let state-licensed pharmacies and outsourcing facilities compound versions of these drugs under special rules. After the shortages were resolved, FDA set end dates for that flexibility. Those periods ended between March and May 2025. The last one, for semaglutide outsourcing facilities, ended May 22, 2025.

FDA's current position, as updated April 1, 2026, includes these points:

  • Compounded drugs are not FDA approved. FDA says it does not review them for safety, effectiveness, or quality before they are marketed.
  • For a state-licensed pharmacy to rely on the usual compounding exemption, the drug must be compounded for an individual patient based on a prescription. The compounder must not make "essentially copies" of a commercially available drug regularly or in inordinate amounts, unless a prescriber documents a significant difference for that patient.
  • Outsourcing facilities generally cannot compound from bulk substances unless the substance is on FDA's 503B bulks list or the drug is on FDA's shortage list. FDA says semaglutide and tirzepatide are on neither.
  • On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. We could not confirm a final decision, so check FDA's site for the latest.

FDA has also received reports of adverse events tied to compounded versions, including dosing mistakes. As of May 31, 2026, FDA had received 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide. FDA notes that underreporting is likely. If a pharmacy offers a compounded product in place of the brand on your prescription, ask your prescriber and your pharmacist about it before you accept.

What new GLP-1 options have been approved?

  • The Wegovy pill. Novo Nordisk announced FDA approval on December 22, 2025. It is a once-daily oral semaglutide for adults with obesity, or overweight with a weight-related condition, and to lower the risk of major cardiovascular events in certain adults. The company said the starting dose would reach pharmacies and select telehealth providers in early January 2026.
  • Foundayo (orforglipron). FDA approved this once-daily oral GLP-1 tablet on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has a boxed warning for thyroid C-cell tumors.
  • Rybelsus tablets. FDA's discontinuation list shows Novo Nordisk discontinuing Rybelsus 3 mg, 7 mg, and 14 mg tablets, posted June 4, 2026. The entry says they will be replaced by Ozempic (semaglutide) tablets. One state Medicaid notice said patients would not be switched automatically and a new prescription would be needed. If you take Rybelsus, ask your prescriber and pharmacist how this affects your plan.

A new product can be hard to find at first. If your prescriber chooses one of these, ask pharmacies whether they carry it before you ask for the prescription to be sent.

Why do insurance and coverage make this harder?

Coverage rules differ by plan, and they change. Many plans require prior authorization. A stock problem and a coverage problem can look the same at the counter. Ask the pharmacist a clear question: "Is the problem that you don't have it, or that the claim was rejected?"

If you have Medicare drug coverage, the Medicare GLP-1 Bridge is a temporary CMS demonstration running from July 1, 2026 through December 31, 2027. It covers Foundayo, Wegovy (injection or tablet), and the Zepbound KwikPen, but not Zepbound vials or single-dose pens. The copay is $50 for a one-month supply. It does not count toward your Part D deductible or out-of-pocket limit. A prior authorization is required, and people with type 2 diabetes, among others, are excluded. Call 1-800-MEDICARE or visit Medicare.gov to check your eligibility.

Savings cards and manufacturer programs can also affect price. Our post on prescription savings cards explains how they work and what they cannot do.

How do I find a pharmacy that has my dose?

  1. Get the exact details. Brand name, strength, and form. For example, a pen, a vial, or a tablet. Write down the quantity too.
  2. Call your current pharmacy. Ask: "Do you have it today? Is it on order? When is the next delivery?"
  3. Call other pharmacies. Check chains, independents, and grocery pharmacies. Say you need the FDA-approved brand product as prescribed.
  4. Ask what they carry regularly. A pharmacist may know which strengths they can usually get.
  5. Ask your prescriber's office to send the prescription to a pharmacy that confirms it has your strength.

Our step-by-step guide to asking a pharmacy if a medication is in stock has a ready-to-read script.

Can Needle help?

Needle phones pharmacies for you, using AI voice agents and human callers, and asks for the exact medication, strength, and form. It reports back which pharmacies said they have it. When a pharmacy reports a medication in stock, Needle attaches a prescription savings card you can use. Its database covers 60,000+ US pharmacies. See pricing, or start a search at app.findneedle.co.

Frequently asked questions

Is Ozempic still in shortage?

No. FDA determined the semaglutide injection shortage resolved on February 21, 2025. As of October 14, 2026, FDA's shortage list has no current semaglutide injection entry. Your pharmacy may still be out of a specific strength.

Is Zepbound or Mounjaro still in shortage?

No. FDA determined the tirzepatide injection shortage resolved on December 19, 2024. A shortage ruling covers the national supply, so you can still run into a gap in your pharmacy's stock.

Are compounded semaglutide and tirzepatide still available?

Some compounded products may still be offered, but FDA's policy has tightened. FDA says it considers a compounded product "essentially a copy" of an approved drug if it has the same active ingredient in a similar strength and route, unless a prescriber documents a significant difference for an identified patient. Ask your prescriber and pharmacist whether any compounded product is appropriate for you.

Is there a GLP-1 pill?

Yes. FDA-approved oral options for weight management include the Wegovy pill, announced December 22, 2025, and Foundayo, approved April 1, 2026. Whether either is right for you is a decision for you and your prescriber.

Sources